Literature DB >> 20049472

Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis.

Su Hyun Kim1, Sung Min Kim, Angela Vincent, Suk Won Ahn, Yoon Ho Hong, Kyung Seok Park, Jung Joon Sung, Kwang Woo Lee.   

Abstract

Longitudinally extensive transverse myelitis (LETM) is a syndrome with extensive spinal cord lesions spanning three or more vertebral segments on spinal cord MRI. Although many reports have indicated that LETM is a characteristic feature of neuoromyelitis optica (NMO) in Western countries, the clinical characteristics and risk for development of NMO in Korean patients with LETM is not clear. We retrospectively investigated the clinical, laboratory, radiological features, and prognosis of Korean patients with a first-ever episode of idiopathic LETM. Patients were classified into four subgroups, depending on their clinical course: monophasic LETM, recurrent LETM, NMO, and classic multiple sclerosis (MS). We compared various clinical, laboratory, and radiological features between groups. Of 20 patients with first-ever LETM, 15 (75%) were men, and 13 (65%) experienced clinical relapse over a mean follow-up period of 58 months. Three of 20 patients (two with NMO, one with recurrent myelitis) were seropositive for anti-AQP4 antibodies. The predominance of men in the monophasic and recurrent LETM groups compared to the NMO group was remarkable. In conclusion, Korean patients with LETM are predominantly male and have low seropositivity for anti-AQP4 antibody, which distinguishes them from LETM patients in Western countries. Patients with LETM and seropositivity for anti-AQP4 antibody have a high risk of relapse. The male predominance and the relatively low seropositive rate for anti-AQP4 suggests that rather than being a limited form of NMO, recurrent LETM is a new clinical entity in Koreans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049472     DOI: 10.1007/s00415-009-5438-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

1.  Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings.

Authors:  Jen Jen Su; Manabu Osoegawa; Takeshi Matsuoka; Motozumi Minohara; Masahito Tanaka; Takaaki Ishizu; Futoshi Mihara; Takayuki Taniwaki; Jun-ichi Kira
Journal:  J Neurol Sci       Date:  2005-12-27       Impact factor: 3.181

2.  Transverse myelitis. Comparison with spinal cord presentations of multiple sclerosis.

Authors:  T F Scott; K Bhagavatula; P J Snyder; C Chieffe
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

3.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

Review 5.  Proposed diagnostic criteria and nosology of acute transverse myelitis.

Authors: 
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

Review 6.  Neuromyelitis optica and asian phenotype of multiple sclerosis.

Authors:  Jun-ichi Kira
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

7.  Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database.

Authors:  W Qiu; J-S Wu; M-N Zhang; T Matsushita; J-i Kira; W M Carroll; F L Mastaglia; A G Kermode
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-08-25       Impact factor: 10.154

8.  Spinal-cord MRI in multiple sclerosis.

Authors:  Geert Lycklama; Alan Thompson; Massimo Filippi; David Miller; Chris Polman; Franz Fazekas; Frederik Barkhof
Journal:  Lancet Neurol       Date:  2003-09       Impact factor: 44.182

9.  T1 hypointensity of the spinal cord in multiple sclerosis.

Authors:  N A Losseff; L Wang; D H Miller; A J Thompson
Journal:  J Neurol       Date:  2001-06       Impact factor: 4.849

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  5 in total

1.  Acute transverse myelitis in demyelinating diseases among the Chinese.

Authors:  R Li; W Qiu; Z Lu; Y Dai; A Wu; Y Long; Y Wang; J Bao; X Hu
Journal:  J Neurol       Date:  2011-05-18       Impact factor: 4.849

2.  Anti-AQP(4) antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis.

Authors:  Marina Papais Alvarenga; Regina Maria Papais Alvarenga; Marcos Papais Alvarenga; Adriano Miranda Santos; Luiz Claudio Santos Thuler
Journal:  J Spinal Cord Med       Date:  2012-07       Impact factor: 1.985

3.  Serological markers associated with neuromyelitis optica spectrum disorders in South India.

Authors:  Lekha Pandit; Douglas Kazutoshi Sato; Sharik Mustafa; Toshiyuki Takahashi; Anitha D'Cunha; Chaithra Malli; Akshatha Sudhir; Kazuo Fujihara
Journal:  Ann Indian Acad Neurol       Date:  2016 Oct-Dec       Impact factor: 1.383

4.  Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica.

Authors:  Jean-Baptiste Chanson; Melissa Alame; Nicolas Collongues; Frédéric Blanc; Marie Fleury; Gabrielle Rudolf; Jérôme de Seze; Thierry Vincent
Journal:  Clin Dev Immunol       Date:  2013-04-28

Review 5.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.